二甲双胍（Glucophage，格华止）会扰乱正常代谢，并（通过阻断Cori循环而自动地）引起乳酸酸中毒。
原始表述
أدوية مثل الجلوكوفاج والفورسيجا تعطّل العمليات الأيضية الطبيعية للجسم، وتتسبب في مضاعفات مثل الحماض اللاكتيكي أو الكيتوني.
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
二甲双胍（Glucophage，格华止）会扰乱正常代谢，并（通过阻断Cori循环而自动地）引起乳酸酸中毒。
出处
- 来源状态
- 档案网站引语（未注明出处）
- 归属
- Elawady (archive paraphrase; source video not given)
- 出处
- https://eltayebat.com/rule/oral-diabetes-drugs/
- 归属的不确定性
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. 'Glucophage causes acidity in the blood' is found (5QU3gO-o0Mg). The mechanism 'by blocking the Cori cycle' was not checked verbatim.
- 所声称的机制
Metformin inhibits hepatic gluconeogenesis from lactate (Cori cycle), so lactate accumulates.
- 所声称的健康影响
Lactic acidosis
- 涉及人群
Metformin users
- Elawady 设定的地域限制
none found
来源版本存在差异
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- الغيبوبات السكرية ؟! (打开来源)
- 发布日期
- 2025年4月30日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
بوديز وسكره مظبوط اه واحد بياخد جلوكوفاج عشان يخس او عيان عنده سكر وبياخد جلوكوفاج وسكر سكره عالي شويه ويخش بلاكتيك اسيدوزيس يبقى معنى كده يا باشا القصه مش قصه انسولين ومش قصه
Glucophage (metformin), taken for weight loss or for diabetes, can cause lactic acidosis even when blood sugar is normal or only slightly raised.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr.D Clinics - Diaa Al Awady is live! الغيبوبة الكيتونية (打开来源)
- 发布日期
- 2025年4月23日
- 时间戳
- 0:45:04 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
غيبوبه ده بس سكره مظبوط بس عنده حموضه في الدم الجلوكوفاج بيعملها يبقى سكر او سكره يوجوال ومعاه حموضه الجلوكفاج بيعملها يا باشا صح
...coma; his sugar is just right but he has acidity in the blood - Glucophage does that; so his sugar is usual and with it acidity - Glucophage does that, sir, right.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! التراكمي عال و السكر واطيي (打开来源)
- 发布日期
- 2025年10月5日
- 时间戳
- 1:36:54 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Close paraphrase of the metformin/acidosis part.
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
Metformin causes lactic acidosis.
2. 哪些内容可证实是正确的？
Metformin lowers hepatic glucose production; in situations of severe kidney failure, shock or hypoxia it can accumulate, and labels advise caution. ADA 2026 advises considering holding metformin when oral intake cannot be maintained (I-INS-10).
3. 哪些内容是错误或夸大的？
Cochrane: 'no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use'; upper limit 4.3 vs 5.4 cases per 100,000 patient-years for non-metformin; no difference in lactate levels (I-ODD-08). Metformin reduced all-cause mortality by 36% in overweight patients in UKPDS 34 (I-ODD-01) and was associated with lower mortality at 10 years (I-INS-02). The archive's own cited cohorts used metformin as the reference with the lowest risk (A-INS-08, A-ODD-07).
4. 哪些内容仍不明确？
Exact incidence in people with advanced kidney disease.
5. 哪些研究支持该说法？
Mechanism; label warnings; association with acidosis at eGFR <30 (HR 2.07) in a large cohort (I-ODD-101); ADA 2026 (I-INS-10, I-ODD-16).
6. 哪些研究与该说法相矛盾？
I-ODD-08 (Cochrane: no cases in 70,490 patient-years), I-ODD-102 (incidence 3-10/100,000 PY, like background), I-ODD-101 (no association at eGFR >=30), I-ODD-01, I-INS-02.
7. 对德国和欧洲而言情况如何？
Metformin is first-line therapy in EU/German guidelines with eGFR-based dose limits.
8. 关于埃及的已知情况是什么？
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. 合理的实际结论是什么？
与二甲双胍相关的乳酸酸中毒非常罕见，而且大多与属于禁忌证的情况有关。二甲双胍是最安全、研究最充分的糖尿病药物之一；应定期检查维生素B12（见C-ODD-07）。
评估详情
- 证据确定性的依据
Mechanistic kernel (metformin reduces hepatic gluconeogenesis, including from lactate) and rare cases, mainly with severe kidney failure, hypoxia or overdose, are real. A Cochrane review of 347 trials/cohorts (70,490 patient-years) found no case of lactic acidosis and no difference in lactate (I-ODD-08); a systematic review puts the incidence at about 3-10 per 100,000 patient-years, indistinguishable from background (I-ODD-102); a cohort of 75,413 patients with time-updated kidney function found no association at eGFR >=30 (HR 0.98) and an association only at eGFR <30 (HR 2.07) (I-ODD-101). ADA 2026 states the complication is very rare and occurs primarily at eGFR <30. The evidence is consistent and precise, so certainty is high that lactic acidosis is not an automatic effect.
- 来源质量
Archive paraphrase plus own words.
- 地区可推广性
Universal.
- 个体例外情况
Severe kidney impairment, shock, hypoxia, alcohol excess and contrast/surgery situations require dose adjustment or pausing.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: In people with type 2 diabetes, does metformin use cause lactic acidosis regularly ('automatically'), and how large is the risk compared with other glucose-lowering treatment across levels of kidney function?
研究问题详解 (PICO)
- 人群
- Adults with type 2 diabetes
- 干预或暴露
- Metformin
- 对照
- Other glucose-lowering drugs or no metformin
- 地域范围
- universal biology
- 结局指标
- Lactic acidosis / hospitalisation with acidosis
- Lactate concentration
- All-cause mortality
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Metformin and blood acid build-up depend on kidney function
Lazarus B et al.. JAMA Intern Med 2018 · PMID 29868840 · DOI 10.1001/jamainternmed.2018.0292 队列研究已核查摘要新增Large cohort with time-updated kidney function: metformin was linked to acidosis only when eGFR was below 30.
- 实际结果
- eGFR <30: adjusted HR 2.07 (1.33-3.22); overall HR 0.98 (0.89-1.08).
- 方法学质量
- moderate (large observational cohort with replication)
- 相关性
- direct - shows the real, condition-dependent kernel of the claim
- 局限
- Administrative outcome code; observational.
哪些证据不支持该说法？
Metformin and lactic acidosis: Cochrane review
Salpeter SR et al.. Cochrane Database Syst Rev 2010 · PMID 20393934 · DOI 10.1002/14651858.CD002967.pub4 系统综述已核查摘要Cochrane review of 347 trials and cohorts found no case of lactic acidosis with metformin.
- 实际结果
- 0 cases in 70,490 patient-years; upper 95% limit 4.3 vs 5.4 per 100,000 patient-years for non-metformin; no difference in lactate.
- 方法学质量
- high (Cochrane systematic review)
- 相关性
- direct
- 局限
- Trials excluded many high-risk patients.
Metformin and blood acid build-up depend on kidney function
Lazarus B et al.. JAMA Intern Med 2018 · PMID 29868840 · DOI 10.1001/jamainternmed.2018.0292 队列研究已核查摘要新增No association with acidosis at eGFR 30 or above in 75,413 patients.
- 实际结果
- Overall HR 0.98 (0.89-1.08); eGFR 30-44 HR 1.09 (0.83-1.44).
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Observational.
Lactic acidosis with metformin is rare, even with mild kidney disease
Systematic review: incidence 3-10 per 100,000 patient-years, indistinguishable from background in diabetes.
- 实际结果
- About 3-10/100,000 PY.
- 方法学质量
- moderate (systematic review, narrative)
- 相关性
- direct
- 局限
- No pooled estimate.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Metformin does not cause lactic acidosis automatically. It reduces hepatic gluconeogenesis (including from lactate), but in normal use lactic acidosis is very rare (about 3-10 per 100,000 patient-years, not more than with other drugs). The risk rises in severe kidney impairment (eGFR <30), overdose, shock or hypoxia, which are contraindications or reasons to pause the drug.
为什么有些研究权重更大
A Cochrane review of 347 studies and a large cohort with time-updated kidney function outweigh case reports and mechanistic reasoning; the 2026 ADA Standards summarise the same evidence.
因果关系是否已确立？ 是，已确立 Causality is established only for the rare situation of metformin accumulation (kidney failure, overdose); a regular ('automatic') causal effect is refuted.
仍存在的不确定性
Exact risk during acute kidney injury or dehydration, e.g. during prolonged fasting.
合理的结论
The 'automatic' lactic acidosis claim is false; a rare, condition-dependent risk is real and is managed by kidney-function-based dosing.
为什么研究结果看起来互相矛盾？
Case reports of metformin-associated lactic acidosis and the null findings of Cochrane are not in conflict: case reports describe rare events mostly in contraindicated situations, while population data show that such events are not more frequent than with other drugs.
这是否取决于国家？
- 一般生物学效应
- Drug pharmacology and physiology are universal. eGFR thresholds for metformin are the same in US, EU and UK guidance.
- 饮食习惯
- Prolonged fasting, Ramadan fasting and very-low-carbohydrate eating change the risk of hypoglycaemia and ketoacidosis with some drugs; relevant in Egypt and among Muslims in Europe.
- 食品原产地
- Not applicable.
- 污染物
- Not applicable.
- 本国生产条件
- Not applicable (same active substances; generics widely used in Egypt).
- 法律规则
- Drug labels and warnings are set by FDA/EMA and national regulators; Egyptian labelling not reviewed.
- 实际监测数据
- No Egypt-specific pharmacovigilance data were found for this outcome.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Log-symmetry of HR confidence intervals by eGFR stratum – All four HR CIs symmetric on the log scale; eGFR<30 HR 2.07 (SE log 0.23). 已重新计算
- Conversion of incidence to absolute terms – 3-10 per 100,000 PY = 1 case per 10,000-33,000 patient-years. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Lactic acidosis with metformin vs other glucose-lowering treatment (eGFR >=30)
- 起始等级
- 高（随机试验）
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (Diabetes Care 2026;49 Suppl 1) (2026) · 原始文献
Metformin may be safely used at eGFR >=30; very high levels (overdose, acute kidney injury) have been associated with lactic acidosis, but this is very rare and primarily occurs at eGFR <30; periodic B12 testing suggested. - ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · 原始文献
Consider holding metformin and SGLT2 inhibitors when oral intake cannot be maintained or acute kidney injury is suspected.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | (TITLE:"metformin") AND (TITLE:"lactic acidosis") AND (kidney OR "renal function" OR eGFR) AND (cohort OR "case-control") | 支持性证据 | 56 | |
| Europe PMC | 2026年10月26日 | (TITLE:"metformin") AND ("lactic acidosis") AND ("systematic review" OR "meta-analysis") | 反对性证据 | 499 | |
| PubMed | 2026年10月26日 | metformin[ti] AND "lactic acidosis"[tiab] AND (incidence[tiab] OR risk[tiab]) AND 2015:2026[dp] | 支持性证据 | 221 | |
| PubMed | 2026年10月26日 | metformin[ti] AND (lactate[tiab] OR "lactic acidosis"[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) | 反对性证据 | 64 | |
| ADA Standards of Care 2026, Section 9 (PubMed Central) | 2026年10月26日 | Fetched https://pmc.ncbi.nlm.nih.gov/articles/PMC12690185/; keyword review: lactic acidosis, eGFR, B12. The diabetesjournals.org DOI landing pages returned HTTP 403; the identical article was read in PubMed Central. | 指南 | 1 |
待解决的问题
Risk during prolonged fasting with dehydration has not been quantified.
核查深度如何？
7 项相关研究：2 项核查了全文（其中 0 项进行了结构化偏倚风险评估），5 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 基本错误 (中) → 基本错误 (高)
Verdict unchanged. Certainty raised to high: the Cochrane review is now complemented by a large cohort with time-updated kidney function and replication (I-ODD-101), a systematic review (I-ODD-102) and the ADA 2026 Standards, all consistent that lactic acidosis is very rare and confined mainly to eGFR <30.
新来源: I-ODD-101 I-ODD-102
通俗解释
二甲双胍在理论上有导致血液中酸性物质积聚的风险，主要见于肾功能很差或病情严重的人。一项涵盖300多项研究的大型综述在约70,000患者年中没有发现一例这样的病例。在一项长期的英国研究中，使用二甲双胍的人寿命更长。当肾功能衰竭或患严重疾病时，医生会调整或暂停二甲双胍。
与该说法相关的研究
支持该说法的研究 (1)
-
ADA guideline 2026: blood sugar goals and emergencies
American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006指南 / 立场声明独立交叉核查已核查全文★ 关键研究Most adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Glycaemic goals, hypoglycaemia and hyperglycaemic crises
- 研究是如何开展的？
Clinical practice guideline (ADA Standards of Care 2026, Section 6)
- 研究了多少人、动物或样本？
not applicable; People with diabetes
- 实际发现了什么？
Individual targets; do not stop basal insulin when not eating.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Moderate targets and safety rules.
- 该研究有哪些局限？
US-centred; Partially read
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Consistent with EASD guidance.
- 从该研究中明确不能得出什么结论？
Not applicable.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (5)
-
Metformin and lactic acidosis: Cochrane review
Salpeter SR et al.. Cochrane Database Syst Rev 2010 · PMID 20393934 · DOI 10.1002/14651858.CD002967.pub4系统综述独立交叉核查已核查摘要★ 关键研究No lactic acidosis cases in about 70,000 patient-years of metformin use.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Incidence of lactic acidosis and lactate levels with metformin
- 研究是如何开展的？
Cochrane systematic review of comparative trials and cohorts
- 研究了多少人、动物或样本？
347 studies; 70,490 metformin vs 55,451 non-metformin patient-years; Type 2 diabetes in trials/cohorts >=1 month
- 实际发现了什么？
No cases; no lactate difference.
- 观察到的效应有多大？
Upper limit 4.3/100,000 PY
- 研究结果对日常生活意味着什么？
Metformin acid build-up is extremely rare.
- 该研究有哪些局限？
Trials often excluded high-risk patients
- 它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-01.
- 研究结果是否适用于德国和欧洲？
International.
- 从该研究中明确不能得出什么结论？
Risk in severe kidney failure.
-
Metformin in overweight type 2 diabetes (UKPDS 34)
UKPDS Group. Lancet 1998 · PMID 9742977随机对照试验独立交叉核查已核查摘要★ 关键研究Metformin reduced deaths from any cause by about a third over 10 years.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Intensive control with metformin in overweight type 2 diabetes
- 研究是如何开展的？
RCT within UKPDS (UKPDS 34)
- 研究了多少人、动物或样本？
753 (main comparison); Overweight newly diagnosed type 2 diabetes, mean age 53
- 实际发现了什么？
Mortality -36%.
- 观察到的效应有多大？
RR reduction 36% (9-55)
- 研究结果对日常生活意味着什么？
Metformin is protective.
- 该研究有哪些局限？
Small arms; Open-label; Conflicting supplementary result
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK.
- 从该研究中明确不能得出什么结论？
Effects in non-overweight patients.
-
UKPDS legacy: 10 years after the trial
Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470随机对照试验独立交叉核查已核查摘要★ 关键研究People treated intensively early with sulfonylureas or insulin had 15% fewer heart attacks and 13% fewer deaths years later.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Do UKPDS benefits persist and do macrovascular effects emerge?
- 研究是如何开展的？
Post-trial monitoring of an RCT (UKPDS 80)
- 研究了多少人、动物或样本？
4,209 randomised; 3,277 monitored; Newly diagnosed type 2 diabetes from UKPDS
- 实际发现了什么？
Legacy reductions in MI and death.
- 观察到的效应有多大？
Death -13% (SU/insulin), -27% (metformin)
- 研究结果对日常生活意味着什么？
Early good control pays off for decades.
- 该研究有哪些局限？
Post-trial therapy not controlled; Questionnaire follow-up
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK; directly relevant.
- 从该研究中明确不能得出什么结论？
Effects of extreme targets in late disease.
-
ADA guideline 2026: diabetes medicines
American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009指南 / 立场声明独立交叉核查已核查全文★ 关键研究Insulin is essential in type 1 diabetes; SGLT2/GLP-1 drugs are recommended for heart and kidney protection; side effects listed.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Pharmacologic glycaemic treatment
- 研究是如何开展的？
Clinical practice guideline (ADA Standards of Care 2026, Section 9)
- 研究了多少人、动物或样本？
not applicable; People with type 1 and type 2 diabetes
- 实际发现了什么？
See results.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Medicines chosen by benefit-risk.
- 该研究有哪些局限？
Partially read
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Consistent with ADA/EASD consensus.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
Lactic acidosis with metformin is rare, even with mild kidney disease
Inzucchi SE et al.. JAMA 2014 · PMID 25536258 · DOI 10.1001/jama.2014.15298系统综述独立交叉核查已核查摘要About 3-10 cases per 100,000 patient-years, similar to the background rate in diabetes.
Incidence indistinguishable from background in people with diabetes.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Review the lactic acidosis risk of metformin in kidney disease.
- 研究是如何开展的？
Systematic literature review, narrative synthesis.
- 研究了多少人、动物或样本？
65 studies.
- 实际发现了什么？
Very low incidence; lactate not substantially raised at eGFR 30-60.
- 观察到的效应有多大？
3-10 per 100,000 person-years.
- 研究结果对日常生活意味着什么？
Lactic acidosis is a rare event, not a regular effect of metformin.
- 该研究有哪些局限？
No pooled analysis; few trials.
- 它对 Elawady 的具体说法说明了什么？
Refutes 'automatic' lactic acidosis.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Exact risk in severe kidney failure.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
Metformin and blood acid build-up depend on kidney function
Lazarus B et al.. JAMA Intern Med 2018 · PMID 29868840 · DOI 10.1001/jamainternmed.2018.0292队列研究独立交叉核查已核查摘要★ 关键研究In 75,413 people, metformin was not linked to acidosis overall (HR 0.98) but was linked when kidney function was severely reduced (eGFR <30: HR 2.07).
Supports the kernel (risk exists at eGFR<30) but contradicts 'automatically': no association at eGFR >=30.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
To measure acidosis risk with metformin at different levels of kidney function.
- 研究是如何开展的？
Health-record cohort with time-updated kidney function, replicated in a second large US data set.
- 研究了多少人、动物或样本？
75,413 people with diabetes; replication with about 82,000 new users.
- 实际发现了什么？
No higher acidosis risk at eGFR 30 or above; about twice the risk below eGFR 30.
- 观察到的效应有多大？
HR 0.98 overall; HR 2.07 (1.33-3.22) at eGFR <30.
- 研究结果对日常生活意味着什么？
Metformin is safe for most kidneys; doctors stop it when kidney function becomes very poor.
- 该研究有哪些局限？
Observational; acidosis code is not specific for metformin-related lactic acidosis.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'automatic' lactic acidosis; confirms a risk in a contraindicated situation.
- 研究结果是否适用于德国和欧洲？
High; same drug and thresholds.
- 从该研究中明确不能得出什么结论？
It cannot exclude rare cases during acute illness or dehydration.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Metformin is first-line therapy in EU/German guidelines with eGFR-based dose limits.
埃及
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
在我的国家适用什么？
一般科学评估
基本错误 基本错误：二甲双胍引起的乳酸酸中毒非常罕见（约每100,000患者年3-10例），主要发生在严重肾衰竭、药物过量或休克时，而不是自动发生的。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.. Salpeter SR et al.. Cochrane Database Syst Rev 2010 · PMID 20393934 · DOI 10.1002/14651858.CD002967.pub4
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742977
- 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
- Metformin in patients with type 2 diabetes and kidney disease: a systematic review.. Inzucchi SE et al.. JAMA 2014 · PMID 25536258 · DOI 10.1001/jama.2014.15298
- Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.. Lazarus B et al.. JAMA Intern Med 2018 · PMID 29868840 · DOI 10.1001/jamainternmed.2018.0292